Printer Friendly

Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies.

Initial laboratory investigations for possible disorders of B-cell lineage currently require both urine and serum samples (1). B-cell disorders cannot be confidently excluded without analysis of urine samples by existing methods because light chain-only and nonsecretory multiple myelomas account for up to 15%-20% of new diagnoses. In many of these, the serum light chain concentrations are below the detection limits of conventional immunofixation methods. However, most laboratories find it difficult to obtain both serum and urine samples from patients. In this hospital, despite publicity from the laboratory, concurrent urine samples are received from <40% of patients.

Automated immunoassays measuring serum free light chains (FLCs)3 have been developed (2), and their role in detecting and monitoring patients with light chain multiple myeloma, nonsecretory multiple myeloma and primary amyloidosis has recently been reviewed (3). Retrospective studies have shown that serum FLC assays are more sensitive than serum protein electrophoresis (SPEP) or urine protein electrophoresis (UPEP) for the detection of these 3 diseases. Serum FLCs cannot replace SPEP in a screening protocol for monoclonal gammopathies, because they are slightly less sensitive than SPEP for intact immunoglobulin multiple myeloma (4). However, their higher limit of detection for FLC, together with the problem of achieving a high percentage of concurrent urine samples, suggests that serum FLCs, as an alternative to urinalysis and in addition to SPEP might improve the detection of monoclonal gammopathies.

A recent prospective study, on serum samples only, showed that additional patients with B-cell disorders were identified when serum FLC measurement was used with capillary zone electrophoresis (5). Our objectives, in a prospective study with consecutive samples received for SPEP, were to evaluate (a) whether the addition of serum FLCs identified extra patients with monoclonal gammopathies at the time of a first request for SPEP; (b) whether serum FLCs could replace urinalysis for Bence Jones protein (BJP); and (c) the cost and quality implications of routinely measuring serum FLCs.

Materials and Methods

Serum FLC measurement was added to all requests for SPEP received from primary care or hospital sources from August 1 to November 30, 2004. Samples from patients with previous diagnoses of myeloma, Waldenstrom's macroglobulinaemia, and lymphoma were excluded. The study received approval from the local ethics committee. At report authorization, additional requests for SPEP were generated when serum globulins were >48 g/L (excluding chronic liver disease, rheumatoid arthritis, and cases in which SPEP had been carried out in the preceding 6 months) or when serum globulins were <27 g/L. Serum FLCs were also measured on these samples.

We measured [kappa] and [lambda] serum FLC concentrations quantitatively by immunoturbidimetry (The Binding Site) on a Roche modular analyzer (CV for between batch precision: [kappa] = 8%, [lambda] = 3%). SPEP, UPEP, and immunofixation electrophoresis (IFE) were carried out with the Hydrasys system (Sebia). All gels were interpreted by experienced clinical scientists. Serum IFE was routinely performed when a monoclonal band (or suspicion of a band) was seen on SPEP and in all samples demonstrating hypogammaglobulinaemia. For such samples, the SPEP gels were interpreted without reference to the serum FLC results. Serum IFE was carried out in the absence of a band (or suspicion of a band) by SPEP when the serum FLC [kappa]/[lambda] ratios were outside the normal range of 0.261.65 (6). When concurrent urine samples were available, urine total protein was measured (benzethonium chloride, Roche modular analyzer, or 917 analyzer) followed by UPEP (Sebia Hydragel [[beta].sub.1]-[[beta].sub.2] 15/30 gels, HR3 program and acid violet stain); unconcentrated urine was used on the basis of recent recommendations (7). This system has a detection limit of ~10 mg/L of albumin; an albumin calibrator (12 mg/L) was included in each gel to confirm satisfactory detection limit. This was followed by IFE to confirm the presence of BJP when the urine sample was not clearly negative by UPEP or when a monoclonal band or hypogammaglobulinaemia were noted in the serum.

SPEP gels were interpreted visually and categorized as either (a) no abnormality detected, (b) raised globulins (rGlob) when total globulins were above the upper limit of the reference range (>42 g/L) but no specific increase in the gamma-region was evident, (c) polyclonal increase in the gamma-globulin region (pIgs), (d) probable monoclonal gammopathy, i.e. monoclonal band (or suspicion of a band) requiring IFE for confirmation, or (e) hypogammaglobulinaemia when suppression of the [gamma] region was evident (hypogammaglobulinaemia).

Serum total protein (Roche; Biuret method catalog no. 11929917) and albumin (bromcresol purple) (8) were measured on a Roche modular or 917 analyzer.

The annual costs incurred by replacing UPEP and urine IFE with serum FLCs were based on the following assumptions: (a) a urine sample was received with every request for SPEP; (b) postanalytical costs were equivalent for urinalysis and serum FLC analysis; (c) no additional preanalytical costs were incurred by introducing serum FLCs on samples received for SPEP; (d) staff costs for the automated analysis of urine total protein were considered insignificant and not included; (e) no significant additional staff costs were incurred for serum FLC analysis, which was performed on the same analyzer as serum total protein and albumin; (fl estimates were based on costs and workload data (2800 samples for SPEP and serum FLC analysis) for the period spanning Apri12004 to March 2005.

ESTIMATE OF COSTS OF URINE ELECTROPHORESIS AND URINE IMMUNOFIXATION

1. Staff costs in sample reception: a factor of 10 was applied to the number of urine samples to reflect the complexity of handling with transfer to secondary tubes relative to blood samples. Preanalytical costs for UPEP and urine IFE were then estimated as a proportion of all sample reception staff costs.

2. Staff costs (biomedical scientist grade 1) for sample analysis for UPEP and urine IFE.

3. Consumables costs for urine total protein analysis, UPEP, and urine IFE gels.

ESTIMATE OF COSTS OF SERUM IMMUNOFIXATION

1. Staff costs (biomedical scientist grade 1) for serum IFE.

2. Consumables costs for serum IFE.

ESTIMATE OF COSTS OF SERUM FLCS

1. Costs of serum FLC reagent sets, assuming that 80 patient samples could be analyzed from a 100-test reagent set, with the remainder required for sample dilutions and quality control.

The additional costs for introducing serum FLC analysis were then calculated as follows: (Costs of serum FLC reagent sets + Staff and Consumables costs for additional serum IFE generated as a consequence of serum FLC analysis) - (Staff costs in sample reception for UPEP and urine IFE + Staff costs for sample analysis for UPEP and urine IFE + Consumables costs for urine total protein and UPEP and urine IFE gels).

Results

After exclusions (Fig. 1), matched SPEP and serum FLC results were available on samples received during the 4 months of the study from 923 consecutive patients (female: n = 523, ages 17-99 years, median 72 years; male: n = 400, ages 18-99 years, median 69 years). One hundred thirty-three were laboratory-generated requests because of high (n = 117) or low (n = 16) serum globulin concentrations. Paired urine samples were received (within [+ or -]3 weeks) with 370 (40%) of the serum samples.

SPEP AND FLC [kappa]/[lambda] RATIOS

Table 1 shows the distribution of serum FLC [kappa]/[lambda] ratios by SPEP category for the 923 samples. Seventy-one (7.7%) samples had [kappa]/[lambda] ratios outside the reference range of 0.26-1.65. Five hundred fifty-one (97%) of 568 with no abnormality detectable by SPEP had [kappa]/[lambda] ratios within the reference range. By our standard protocol, all samples in the probable monoclonal band (n = 79) and hypogammaglobulinaemia (n = 19) categories would proceed to serum IFE. Of the 825 with "negative" SPEP (i.e., categories rGlob, pigs, and no abnormality detected), 43 (5.2%) had abnormal [kappa]/[lambda] ratios and required serum IFE for the purpose of this study, representing an increase in serum IFE of 44%. Those with high [kappa]/[lambda] ratios have been subdivided into 3 groups ([kappa]/[lambda] ratios of 1.66-3.0, >3-5.0, and >5).

SERUM IMMUNOFIXATION AND FLC [kappa]/[lambda] RATIOS

Table 1 also shows the percentage of samples with abnormal [kappa]/[lambda] ratios in which either a monoclonal band was confirmed by serum IFE or a diagnosis of B-cell disorder was made. As can be seen, the percentages of positives increase as [kappa]/[lambda] ratios rise. When expressed as positive predictive values (PPVs), for a [kappa]/[lambda] ratio cutoff of 1.65, the PPV was 34%,increasing to 58% and 78% when [kappa]/[lambda] ratios of >3.0 or >5.0, respectively, were used as cutoff points. Of particular interest for this study were the 43 patients with abnormal [kappa]/[lambda] ratios (low ratio: n = 1; high ratios: n = 42), but no evidence of monoclonal bands or hypogammaglobulinaemia by SPEP. The results in these 43 are discussed below.

NEGATIVE SPEP BUT MONOCLONAL BANDS BY SERUM IFE (n = 4)

Two of these 4 patients had very small monoclonal bands (<1 g/L); these had rGlob by SPEP. The other 2 had IgA-[kappa] monoclonal bands comigrating with the [beta]-globulins; no abnormality was detected by SPEP. These results are summarized in Table 2 (patients 1-3 and 7).

[FIGURE 1 OMITTED]

NEGATIVE SPEP AND POLYCLONAL IMMUNOGLOBULINS BY SERUM IFE (n = 22)

Twenty-two of the 43 patients showed either a pigs (n = 16) or rGlob (n = 6) by SPEP. Twenty of these 22 were not followed up; in 18, the reason for the initial SPEP was rGlob, and IFE excluded a monoclonal protein as the cause of the rGlob concentration; in 2, infections or inflammation explained the increase in immunoglobulins. The [kappa]/[lambda] ratios in these 20 patients were 1.68-4.55 (mean, 2.46). In 1 patient, IFE revealed an oligoclonal pattern, and bone marrow biopsy showed increased plasma cells and lymphocytes; the patient was subsequently found to be HIV positive ([kappa] = 107, [lambda] = 34.7 mg/L; [kappa]/[lambda] ratio = 3.09). The remaining patient had Sjogreri s syndrome, with initially greatly increased total globulins (120 g/L; IgA, 11.5 g/L; IgG, 78.3 g/L), high serum FLC concentrations ([kappa] = 547 mg/L, [lambda] = 126 mg/L; [kappa]/[lambda] ratio = 4.35) and low glomerular filtration rate (31 mL * [min.sup.-1] * 1.73 [m.sup.-2]). Six months after the initial sample, there was a decrease in serum FLC concentrations ([kappa] = 48 mg/L, [lambda] = 38 mg/L; [kappa]/[lambda] ratio = 1.25), because total globulins (58 g/L) and immunoglobulin concentrations (IgA 6.1 g/L, IgG 28.7 g/L) fell with treatment and glomerular filtration rate improved (66 mL * [min.sup.-1] * 1.73 [m.sup.-2]).

NEGATIVE SPEP AND NO ABNORMALITY BY SERUM IFE (n=17)

Of these patients, 15 showed no abnormality by SPEP, and 2 showed rGlob. One patient with no abnormality detected by SPEP and a low serum FLC [kappa]/[lambda] ratio (0.18, Table 1) was found to have a malignant lymphoma. Ten patients had [kappa]/[lambda] ratios of 1.66-2.18; urine samples from 5 were negative for BJP. Two patients had [kappa]/[lambda] ratios of 3.5 and 5.6; repeat samples after 4-6 months showed normal serum FLC concentrations and [kappa]/[lambda] ratios. Results for the remaining 4 patients are summarized in Table 2 (patients 4-6 and 8). A diagnosis of FLC monoclonal gammopathy of undetermined significance (MGUS) was made in a patient with a [kappa]/[lambda] ratio of 14.6. Light chain multiple myeloma was confirmed in the 2 patients with the highest [kappa]/[lambda] ratios (51.1 and 193). The [kappa]/[lambda] ratio in patient 5 ([kappa]/[lambda] ratio = 29.7) had not changed significantly after 9 months, but the patient declined further investigation at this time. A small [kappa] band was detected in the urine, and it is likely that this patient has a FLC MGUS.

MATCHED SERUM AND URINE SAMPLES

Of the 370 urine samples, 141 (38%) were indeterminate by UPEP; subsequent testing by urine IFE revealed monoclonal [kappa] or [lambda] bands in 15. Eleven of these had abnormal [kappa]/[lambda] ratios (5 with [lambda]-BJP: [kappa]/[lambda] ratios of 0.004-0.13; 6 with [kappa]-BJP: [kappa]/[lambda] ratios of 3.2-855). Four of the patients with positive urine IFE had [kappa]/[lambda] ratios with the reference interval (0.31-1.21) and were therefore potential "false negatives" for the serum FLC assays. However, in 1 patient, SPEP detected a band identified by serum IFE as an IgG-[lambda] paraprotein (7 g/L, [kappa]/[lambda] ratio = 0.31); follow-up samples after 4 months showed similar results ([kappa]/[lambda] ratio = 0.35). No excess plasma cells were seen in a bone marrow biopsy. There were thus 3 patients (of 370) who would not have been followed up if only SPEP and serum FLCs had been measured. In all 3 patients, the BJP concentration was ~50 mg/L. In 1 patient, the BJP resolved when high serum immmunoglobulins, because of a chest infection, normalized; in another, a follow-up urine was negative. Review of the initial urine IFE gel in this patient indicated a pattern more consistent with polyclonal [kappa] light chains, and we consider the initial "positive" report to have been an interpretive error. Only 1 of the 3 patients had a persisting low concentration of BJP in follow-up urine samples. Bone marrow biopsy and skeletal survey did not indicate a B-cell disorder in this patient.

ADDITIONAL ANNUAL COSTS INCURRED BY REPLACING URINE ELECTROPHORESIS AND URINE IMMUNOFIXATION WITH SERUM FLCS

Table 3 shows the estimate of costs and the additional annual costs incurred by replacing UPEP and urine IFE with serum FLCS. Sixty percent of the costs of introducing serum FLC analysis could be offset by savings from UPEP and urine IFE.

Discussion

This prospective study evaluated serum FLCS in 923 consecutive serum samples for which SPEP was requested. Of these sera, 370 had matched urine samples. Together they provide an appropriate large clinical sample with which to evaluate the effectiveness of adding serum FLCS to SPEP and UPEP as first-line tests for B-cell proliferative disorders.

Most samples (92.3%) had normal serum FLC [kappa]/[lambda] ratios. Of those samples for which serum IFE measurement would not have been indicated by SPEP, 94.8% had normal [kappa]/[lambda] ratios. In the 4 months of the study, 98 samples required serum IFE because of possible monoclonal bands or hypogammaglobulinaemia by SPEP, and an additiona143 samples required serum IFE on the basis of abnormal [kappa]/[lambda] ratios alone (Table 1).

A recent report (9) evaluating the performance of serum FLCS in clinical practice found no patients with false-positive [kappa]/[lambda] ratios among 121 patients without monoclonal gammopathies. Unlike that study, in which the majority of requests were from clinical hematology patients, our samples were from primary care patients and from a wide range of clinical specialties within the hospital. Seventy-one (7.7%) of our patients had abnormal [kappa]/[lambda] ratios; 23 of these were found to have monoclonal bands by serum IFE. In an additional 3 patients, either light chain multiple myeloma or light chain MGUS was diagnosed; 1 patient died from lymphoma; and light chain MGUS seems likely in 1 patient, who has refused further investigation. On the basis of the currently accepted reference interval of 0.26-1.65 for the [kappa]/[lambda] ratio, we found 43 false positives and 28 true positives (i.e., an overall PPV for B-cell disorders for an abnormal [kappa]/[lambda] ratio of 39%). The PPV for [kappa]/[lambda] ratios of <0.26 was 67%. For increased [kappa]/[lambda] ratios, the PPV was 34%, 58%, and 78% at [kappa]/[lambda] ratios of >1.65, >3.0, and >5.0, respectively. Our study, in a patient sample population typical of many diagnostic laboratories, shows higher numbers of false positives than those described from a specialist center (9). Similarly, as a prospective screening study that used a stepwise investigation procedure in which urine IFE was not used as a first-line screening tool, a patient with BJP below the limit of detection of the UPEP assay (10 mg/L) and no serum abnormality would not have been identified.

Our data validate the [kappa]/[lambda] ratio reference interval; 551 (97%) of 568 patients in whom no abnormality was detected by SPEP had [kappa]/[lambda] ratios within the reference interval of 0.26-1.65. In the study that defined this reference interval (6), a1125 patients with polyclonal increases in immunoglobulins (defined by SPEP and serum IFE) had normal [kappa]/[lambda] ratios, although [kappa] and [lambda] serum FLC concentrations were increased in 52% and 58%, respectively. Fourteen percent of our 113 patients with polyclonal increases in immunoglobulins had abnormal [kappa]/[lambda] ratios (median, 0.99; range, 0.43-4.55), with increased [kappa] and [lambda] FLC concentrations in 87% and 70%, respectively. Polyclonal increases in immunoglobulins were found in 22 of the 43 samples in which raised [kappa]/[lambda] ratios were the only indication for proceeding to serum IFE; such increases in immunoglobulins were the commonest cause of false-positive [kappa]/[lambda] ratios. In 14 of these samples, the glomerular filtration rate was <60 mL/min, indicating renal impairment (10); in only 1 of the 22 patients was glomerular filtration rate above the mean for age and sex. Our data support the use of the [kappa]/[lambda] ratio reference interval of 0.26-1.65 when SPEP shows no abnormality. However, [kappa]/[lambda] ratios >1.65 have a PPV for a monoclonal gammopathy or B-cell disorder of ~34%,and the broader clinical picture and laboratory data must be taken into account when interpreting serum FLC results.

As with many diagnostic tests, greater experience leads to a better understanding, so interpretation is based on more than just the reference interval. Inevitably, in a general hospital population, there will be patients with various degrees of renal impairment and/or acute phase responses, leading to more false positives. However, our study demonstrated that substantial additional clinical information was gained by adding serum FLCS to SPEP. From the 43 samples with raised [kappa]/[lambda] ratios and "negative" (nondiagnostic) SPEP that would not have indicated the need for serum IFE, [kappa] light chain multiple myeloma was diagnosed in 2 patients and MGUS in 4 (Table 2). An additional patient is likely to have FLC MGUS ratio = 29.7) but has declined further investigation. One patient, initially found to have 2 small monoclonal IgG-[kappa] bands (IgG = 20.4 g/L; [kappa]/[lambda] ratio = 2.1), has progressed to a typical polyclonal increase in IgG with no further increase in IgG, although the [kappa]/[lambda] ratio has increased over 12 months to 3.5; urine BJP is negative, and she has refused further investigation.

In light of this study, we have now adopted SPEP and serum FLCs as our first-line tests for the investigation of possible B-cell disorders. Because no substantial pathology would have been missed by replacing urine BJP with serum FLCs, we no longer require a urine sample as part of the initial screen.

Laboratory protocols vary considerably, making it difficult to estimate the proportional increase in costs through adding serum FLCs as a first-line test. As Table 3 shows, the consumables for serum FLCs are expensive; in addition, laboratory costs were higher because the introduction of serum FLCs increased the indication for serum IFE from 10.6% to 15.3% of samples. We estimate (Table 3) that replacing urinalysis with serum FLCs releases revenue and manpower savings, which offset ~60% of the additional costs of serum FLC analysis. However, the quality of the diagnostic service we offer has improved by adding serum FLC analysis; our previous practice was suboptimal, because urine samples were received from only 40% of patients being screened. An additional benefit is that serum FLC measurements are available on our main analyzer within the day for most patients, whereas urine BJP analysis was performed in batches with a turnaround time of ~1 week when urine IFE was also indicated.

We also find that the availability of the serum FLC and [kappa]/[lambda] ratio results at the time of viewing the SPEP gel improves the interpretive process by helping to identify those samples that require serum IFE to detect small monoclonal bands, particularly those hidden in the az or [beta]-globulin regions, and to detect light chain monoclonal bands that may be too small for reliable detection by SPEP.

We gratefully acknowledge the support of Prof. A.R. Bradwell and Dr. G.P. Mead of The Binding Site (Birmingham, United Kingdom) in providing the serum FLC reagent sets and for their helpful scientific advice in planning and implementing this study. We also acknowledge the technical support of J. Mayne and Denise Ablett.

Received February 20, 2006; accepted June S, 2006. Previously published online at DOI: 10.1373/clinchem.2006.069104

References

(1.) Kyle R. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.

(2.) Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80.

(3.) Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005;51:805-7.

(4.) Mead GP, Carr-Smith HD, Drayson MT, Morgan GT, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haemat 2004;126:348-54.

(5.) Bakshi NA, Gulbranson R, Garstka D, Bradwell AR, Keren DF. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M-proteins. Am J Clin Pathol 2005;124:214-8.

(6.) Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free K and free A immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:143744.

(7.) Beetham R. Detection of Bence-Jones protein in practice. Ann Clin Biochem 2000;37:563-70.

(8.) Hill PG, Wells TNC. Bromocresol purple and the measurement of albumin. Ann Clin Biochem 1983;20:264-70.

(9.) Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005;51:87881.

(10.) Levey A, Bosch J, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130: 461-70.

PETER G. HILL, [1] JULIA M. FORSYTH, [1] * BALDEEP RAI, [1] and STEWART MAYNE [2]

Departments of [1] Chemical Pathology and [2] Clinical Haematology, Derbyshire Royal Infirmary, Derby Hospitals National Health Service Foundafion Trust, Derby, United Kingdom. [3] Nonstandard abbreviafions: FLC, free light chain; SPEP, serum protein electrophoresis; UPEP, urine protein electrophoresis; BJP, Bence Jones protein; IFE, immunofixafion electrophoresis; rGlob, raised globulins; pigs, polyclonal increase in the gamma-globulin region; MGUS, monoclonal gammopathy of undetermined significance; PPV, positive predicfive value.

* Address correspondence to this author at: Chemical Pathology Department, Derbyshire Royal Infirmary, London Rd., Derby DE12QY, United Kingdom. Fax 01332-254864; Julia.forsyth@derbyhospitals.nhs.uk.
Table 1. Distribution of serum FLC [kappa]/[lambda] ratios by SPEP
category.

 Serum FLC [kappa]/[lambda] ratio

 Low ratio Normal ratio
 All (<0.26) (0.26-1.65)

SPEP n (%Pos) n (%Pos) n (%Pos)

prMG (a) 79 (72) 9 (89) 57 (70)
Hypo 19 (16) 5 (20) 13 (8)
rGlob 144 0 134
pIgs 113 0 97
NAD 568 1 (100) 551
Total 923 15 (67) 852

 Serum FLC [kappa]/[lambda] ratio

 High ratio (>1.65)

 1.66-3 >3-5 >5

SPEP n (%Pos) n (%Pos) n (%Pos)

prMG (a) 7 (57) 4 (100) 2 (50)
Hypo 0 0 1 (100)
rGlob 110 (20) 0 0
pIgs 111 (0) 5 (0) 0
NAD 5 9 (11) 1 (100) 6 (83)
Total 937 (19) 10 (50) 9 (78)

(a) The %Pos columns indicate the percentage in which a monoclonal
band was detected by serum IFE or a subsequent diagnosis of a B-cell
disorder was made.

Abbreviations: prMG, probable monoclonal band; Hypo,
hypogammaglobulinaemia; NAD, no abnormality detected.

Table 2. Results in 8 patients with abnormal serum FLC
[kappa]/[lambda] ratios and negative SPEP.

 Patient Serum results

 Age, M band, [kappa] [lambda]
No. years Sex SPEP IFE (a) g/L mg/L mg/L

1 71 M rGlob IgA-[kappa] 8 21.3 12
2 84 F rGlob IgG-[kappa] <1 52.1 25
3 54 F NAD IgA-[kappa] 5 17.1 7.1
4 70 M NAD NAD 293 20
5 72 F NAD NAD 310 10.4
6 82 F NAD NAD 537 10.5
7 72 F NAD IgA-[kappa] <1 778 12
8 42 M NAD NAD 2601 13.5

Patient Urine results

 Age, [kappa]/
No. years [lambda] UPEP IFE GFR Diagnosis/other details

1 71 1.72 Neg Neg IgA MGUS, skeletal
 survey shows no
 abnormality
2 84 2.11 Neg Neg 50 Progressed to poly-
 clonal IgG; declined
 further
 investigations
3 54 2.52 Neg Neg 88 IgA MGUS, no change in
 IgA in 6 months
4 70 14.6 Pos [kappa] 24 FLC MGUS; bone marrow
 biopsy: normal
5 72 29.7 Pos [kappa] 59 Probable FLC MGUS;
 declined further
 investigations
6 82 51.1 Pos [kappa] 53 LCMM confirmed
7 72 63.7 Pos [kappa] 55 IgA MGUS; bone marrow
 biopsy: normal
8 42 193 Pos [kappa] 24 LCMM confirmed

(a) M band, monoclonal band; GFR, glomerular filtration rate
(mL/min/1.73[m.sup.-2]); rGlob, raised globulins; Neg, negative; NAD,
no abnormality detected; Pos, positive; LCMM, light chain multiple
myeloma.

Table 3. Estimate of additional annual costs and additional
cost/patient incurred by replacing urine electrophoresis
and urine immunofixation with serum FLCs for a workload
of 2800 patient samples.

 [pounds sterling]

1. Costs of urine electrophoresis and urine
 immunofixation
 Staff costs in sample reception 3855
 Staff costs for sample analysis 7320
 Consumables costs 9490
2. Costs of additional serum immunofixation
 Staff costs for additional serum IFE 1221
 Consumables costs for additional serum IFE 951
3. Costs of serum FLCs
 Consumables costs 31 734
4. Additional annual costs incurred = [pounds 13 241
 sterling] (all of category 2 above + all
 of category 3 above) - all of category
 1 above
 Additional cost per patient 4.73
COPYRIGHT 2006 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Hematology
Author:Hill, Peter G.; Forsyth, Julia M.; Rai, Baldeep; Mayne, Stewart
Publication:Clinical Chemistry
Date:Sep 1, 2006
Words:4369
Previous Article:Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry.
Next Article:Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps.
Topics:


Related Articles
Laboratory evaluation of proteinuria.
Setting reference intervals, urine dipstick confirmation, and background stain on Western blotting. (Tips From the Clinical Experts).
Comparison of the sensitivity of 2 automated immunoassays with immunofixation electrophoresis for detecting urine Bence Jones proteins.
Serum free light chain measurements move to center stage.
Serum free light chain specificity and sensitivity: a reality check.
Identification and properties of glycated monoclonal IgA that affect the fructosamine assay.
Medical chemists and the origins of clinical chemistry in Britain (circa 1750-1850).
Development of an enzyme-linked immunosorbent assay with monoclonal antibody for quantification of homovanillic in human urine samples.
Immunochemical quantification of free light chains in urine.
Bence Jones cryoglobulinuria: characterization of a urinary [kappa] light chain cryoglobulin.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters